Evidence map›Paper›PMID 37433130›Full record

ArticleACS infectious diseases2023

Nanoscaled Discovery of a Shunt Rifamycin from

Nhan T Pham, Joana Alves, Fiona A Sargison, Reiko Cullum, Jan Wildenhain, William Fenical, Mark S Butler, David A Mead, Brendan M Duggan, J Ross Fitzgerald and 2 more

Open access · hybridAbstract read
In one paragraph

Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Nhan T PhamSchool of Biological Sciences, The University of Edinburgh, The King's Buildings, Edinburgh EH9 3BF, U.K.ORCID 0000-0003-1620-2910
Joana AlvesThe Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, U.K.
Fiona A SargisonThe Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, U.K.
Reiko CullumCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, California 92093-0204, United States.
Jan WildenhainExscientia Oxford Science Park, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, U.K.
William FenicalCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, California 92093-0204, United States.ORCID 0000-0002-8955-1735
Mark S ButlerXenobe Research Institute, P. O. Box 3052, San Diego, California 92163, United States.ORCID 0000-0001-6689-4236
David A MeadTerra Bioforge Inc., 3220 Deming Way Suite 100, Middleton, Wisconsin 53562, United States.
Brendan M DugganSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.ORCID 0000-0002-7034-8374
J Ross FitzgeraldThe Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, U.K.
James J La ClairXenobe Research Institute, P. O. Box 3052, San Diego, California 92163, United States.ORCID 0000-0001-6500-4107
Manfred AuerSchool of Biological Sciences, The University of Edinburgh, The King's Buildings, Edinburgh EH9 3BF, U.K.ORCID 0000-0001-8920-3522
Roslin Institute · GBScripps Institution of Oceanography · USUniversity of California San Diego · USXenobe Research Institute · USScience Oxford · GBUniversity of Edinburgh · GB

Funding

Targeting the large cyclophilins through an autonomous CONA assayR21NS128597 · NINDS · XENOBE RESEARCH INSTITUTE · PI LA CLAIR, JAMES J, MANFRED, AUER · 2022 to 2022
$423k
Biotechnology and Biological Sciences Research Council BBS/E/D/20002173Biotechnology and Biological Sciences Research Council BBS/E/D/20002174Medical Research Council MR/N02995X/1NINDS NIH HHS R21 NS128597Wellcome TrustWellcome Trust 201531/Z/16/Z
6 · The paper itself

Abstract

Antimicrobial resistance has emerged as a global public health threat, and development of novel therapeutics for treating infections caused by multi-drug resistant bacteria is urgent.

Indexed as

RifamycinsStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsGreen Fluorescent ProteinsHumansMacrophagesMicromonosporaceaeStaphylococcus aureusAnti-Bacterial AgentsGreen Fluorescent ProteinsRifamycinsfluorescence imaging assaymacrophagerifamycinSalinispora arenicolaStaphylococcus aureus

Identifiers

PMID37433130
PMCPMC10425972
OpenAlexW4383894987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.